1. Home
  2. TYRA vs GSL Comparison

TYRA vs GSL Comparison

Compare TYRA & GSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$22.99

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

GSL

Global Ship Lease Inc New

HOLD

Current Price

$34.12

Market Cap

1.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
GSL
Founded
2018
2007
Country
United States
Greece
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Marine Transportation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
TYRA
GSL
Price
$22.99
$34.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
1
Target Price
$32.17
$39.00
AVG Volume (30 Days)
585.9K
447.2K
Earning Date
11-05-2025
11-10-2025
Dividend Yield
N/A
7.46%
EPS Growth
N/A
24.38
EPS
N/A
11.14
Revenue
N/A
$747,044,000.00
Revenue This Year
N/A
$6.69
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.01
Revenue Growth
N/A
6.50
52 Week Low
$6.42
$17.73
52 Week High
$24.05
$37.22

Technical Indicators

Market Signals
Indicator
TYRA
GSL
Relative Strength Index (RSI) 66.44 49.08
Support Level $22.43 $32.74
Resistance Level $23.74 $34.17
Average True Range (ATR) 1.28 0.76
MACD -0.15 -0.41
Stochastic Oscillator 72.08 29.46

Price Performance

Historical Comparison
TYRA
GSL

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About GSL Global Ship Lease Inc New

Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.

Share on Social Networks: